Sex-specific threshold levels of plasma B-type natriuretic peptide for prediction of cardiovascular event risk in a Japanese population initially free of cardiovascular disease

American Journal of Cardiology

Volumn 108, Issue 11, 2011, Pages 1564-1569

  Nakamura, Motoyuki ^a   Tanaka, Fumitaka ^a   Takahashi, Tomohiro ^a   Makita, Shinji ^a   Ishisone, Takenori ^a   Onodera, Masayuki ^a   Ishibashi, Yasuhiro ^a   Itai, Kazuyoshi ^a   Onoda, Toshiyuki ^a   Ohsawa, Masaki ^a   Tanno, Kozo ^a   Sakata, Kiyomi ^a   Shinichi, Omama ^a   Ogasawara, Kuniaki ^a   Ogawa, Akira ^a   Kuribayashi, Toru ^b   Okayama, Akira ^c  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b IWATE UNIVERSITY   (Japan)

^c First Anti Tuberculosis Association   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SEX DIFFERENCE; SEX RATIO; SMOKING;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; SEX DISTRIBUTION; SEX FACTORS; TIME FACTORS;

EID: 80955133286     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2011.07.011     Document Type: Article

References (18)

1. M. Ohsawa, K. Itai, K. Tanno, T. Onoda, A. Ogawa, M. Nakamura, T. Kuribayashi, Y. Yoshida, K. Kawamura, S. Sasaki, K. Sakata, and A. Okayama Cardiovascular risk factors in the Japanese northeastern rural population Int J Cardiol 137 2009 226 235
2. P.A. McKee, W.P. Castelli, P.M. McNamara, P.A. McKee, and M. Feinleib The natural history of congestive heart failure: the Framingham study N Engl J Med 285 1971 1441 1446
3. H. Tunstall-Pedoe, K. Kuulasmaa, P. Amouyel, D. Arveiler, A.M. Rajakangas, and A. Pajak Myocardial infarction and coronary deaths in the World Health Organization MONICA project Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents Circulation 90 1994 583 586
4. World Health Organization MONICA Project Event Registration Data Component, MONICA Manual Version 1.1, Document for Meeting of MONICA Principal Investigators 1986 World Health Organization Geneva, Switzerland
5. S. Matsuo, E. Imai, M. Horio, Y. Yasuda, K. Tomita, K. Nitta, K. Yamagata, Y. Tomino, H. Yokoyama, A. Hishida Collaborators Developing the Japanese Equation for Estimated GFR Revised equations for estimated GFR from serum creatinine in Japan Am J Kidney Dis 53 2009 982 992
6. R.B. D'Agostino Sr, R.S. Vasan, M.J. Pencina, P.A. Wolf, M. Cobain, J.M. Massaro, and W.B. Kannel General cardiovascular risk profile for use in primary care: the Framingham Heart Study Circulation 117 2008 743 753
7. T.J. Wang, M.G. Larson, D. Levy, E.J. Benjamin, E.P. Leip, T. Omland, P.A. Wolf, and R.S. Vasan Plasma natriuretic peptide levels and the risk of cardiovascular events and death N Engl J Med 350 2004 655 663
8. C. Kistorp, I. Raymond, F. Pedersen, F. Gustafsson, J. Faber, and P. Hildebrandt N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults JAMA 293 2005 1609 1616
9. J.H. Rutten, F.U. Mattace-Raso, E.W. Steyerberg, J. Lindemans, A. Hofman, R.G. Wieberdink, M.M. Breteler, J.C. Witteman, and A.H. van den Meiracker Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study Hypertension 55 2010 785 791
10. G.C. Linssen, S.J. Bakker, A.A. Voors, R.T. Gansevoort, H.L. Hillege, P.E. de Jong, D.J. van Veldhuisen, R.O. Gans, and D. de Zeeuw N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population Eur Heart J 31 2010 120 127
11. J.A. de Lemos, and P. Hildebrandt Amino-terminal pro-B-type natriuretic peptides: testing in general populations Am J Cardiol 101 2008 16 20
12. M.M. Redfield, R.J. Rodeheffer, S.J. Jacobsen, D.W. Mahoney, K.R. Bailey, and J.C. Burnett Jr Plasma brain natriuretic peptide concentration: impact of age and gender J Am Coll Cardiol 40 2002 976 982
13. T.J. Wang, M.G. Larson, D. Levy, E.P. Leip, E.J. Benjamin, P.W. Wilson, P. Sutherland, T. Omland, and R.S. Vasan Impact of age and sex on plasma natriuretic peptide levels in healthy adults Am J Cardiol 90 2002 254 258
14. A. Struthers, and C. Lang The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent "pancardiac" target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney Eur Heart J 28 2007 1678 1682
15. M. Nakamura, H. Endo, M. Nasu, N. Arakawa, T. Segawa, and K. Hiramori Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population Heart 87 2002 131 135
16. T.J. Wang, M.G. Larson, D. Levy, E.J. Benjamin, E.P. Leip, P.W. Wilson, and R.S. Vasan Impact of obesity on plasma natriuretic peptide levels Circulation 109 2004 594 600
17. S.R. Das, M.H. Drazner, D.L. Dries, G.L. Vega, H.G. Stanek, S.M. Abdullah, R.M. Canham, A.K. Chung, D. Leonard, F.H. Wians Jr, and J.A. de Lemos Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study Circulation 112 2005 2163 2168
18. P.M. McKie, A. Cataliotti, B.D. Lahr, F.L. Martin, M.M. Redfield, K.R. Bailey, R.J. Rodeheffer, and J.C. Burnett Jr The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects J Am Coll Cardiol 55 2010 2140 2147